Add-on Acquisition • Life Science

Scopus BioPharma Acquires Olimmune

On June 30, 2021, Scopus BioPharma acquired life science company Olimmune

Acquisition Context

This is Scopus BioPharma’s 1st transaction in the Life Science sector.
This is Scopus BioPharma’s 1st transaction in the United States.
This is Scopus BioPharma’s 1st transaction in California.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	June 30, 2021
Target	Olimmune
Sector	Life Science
Buyer(s)	Scopus BioPharma
Deal Type	Add-on Acquisition

Target Company

Olimmune

Los Angeles, California, United States

Olimmune is an immunotherapy company, that develops oligonucleotide therapeutics to treat cancer and other diseases by regulating the immune system. Olimmune was founded in 2019 and is based in Los Angeles, California.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Scopus BioPharma

New York, New York, United States

Category	Company
Founded	2017
Sector	Life Science
Employees	13
Revenue	12M USD (2022)

DESCRIPTION

Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. To achieve its mission, the company seeks to capitalize on ground-breaking scientific and medical discoveries at some of the world’s foremost academic and research institutions. Scopus BioPharma was formed in 2017 and is based in New York City.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: California	1 of 1
Country: United States	1 of 1
Year: 2021	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - California M&A - United States M&A - 2021 M&A